A Phase I Trial of Temsirolimus (CCI-779, Torisel) Combined With Cetuximab (Erbitux) in Cetuximab-Refractory Colorectal Cancer.
Phase of Trial: Phase I
Latest Information Update: 01 Dec 2011
At a glance
- Drugs Cetuximab; Temsirolimus
- Indications Colorectal cancer
- Focus Adverse reactions; Pharmacokinetics
- 01 Dec 2011 Company (Pfizer) added as trial sponsor/affiliate as reported by ClinicalTrials.gov.
- 01 Dec 2011 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.
- 01 Dec 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.